GNAS敲除通过病毒模拟相关干扰素反应增强淋巴瘤对HDAC3抑制的敏感性
研究通过全基因组CRISPR筛选发现GNAS敲除可使耐药淋巴瘤细胞对HDAC3抑制敏感,该致敏作用不依赖经典G蛋白活性,而由病毒模拟相关干扰素反应介导,特征为TBK1和IRF3激活、双链RNA形成及转座子元件表达。GNAS敲除还与HDAC3抑制协同增强CD8+ T细胞诱导的细胞毒性。人淋巴瘤患者中低GNAS表达与高基线转座子元件表达及干扰素信号上调相关,作者提出低GNAS表达可作为反映病毒模拟预激活、预测HDAC3抑制疗效的潜在生物标志物,尤其适用于CREBBP野生型病例。
要点
- GNAS敲除可使耐药淋巴瘤细胞对HDAC3抑制敏感。
- 该致敏作用由病毒模拟相关干扰素反应介导,不依赖经典G蛋白活性。
- 低GNAS表达与高基线转座子元件表达及干扰素信号上调相关。
核心结论
- GNAS敲除通过病毒模拟相关干扰素反应使耐药淋巴瘤细胞对HDAC3抑制敏感,建立了HDAC3抑制与病毒模拟之间的新联系。
- 作者建议将低GNAS表达作为反映病毒模拟预激活、预测HDAC3抑制疗效的潜在生物标志物,尤其适用于CREBBP野生型病例。
研究设计与样本
- 研究采用无偏全基因组CRISPR筛选,鉴定GNAS敲除为耐药淋巴瘤细胞对HDAC3抑制的致敏因素。
- 研究包含机制实验及人淋巴瘤患者样本分析。
主要发现
- GNAS敲除诱导的致敏不依赖经典G蛋白活性,而由病毒模拟相关干扰素反应介导,特征为TBK1和IRF3激活、双链RNA形成及转座子元件表达。
- GNAS敲除与HDAC3抑制协同增强CD8+ T细胞诱导的细胞毒性。
- 人淋巴瘤患者中低GNAS表达与高基线转座子元件表达及干扰素信号上调相关,并与GNAS敲除在组蛋白修饰、mRNA加工和转录调控方面共享共同的 disrupted 生物学活性。
临床怎么用
- 作者建议低GNAS表达可作为反映病毒模拟预激活、预测HDAC3抑制疗效的潜在生物标志物,尤其在CREBBP野生型淋巴瘤的临床治疗中。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite selective HDAC3 inhibition showing promise in a subset of lymphomas with CREBBP mutations, wild-type tumors generally exhibit resistance. Here, using unbiased genome-wide CRISPR screening, we identify GNAS knockout (KO) as a sensitizer of resistant lymphoma cells to HDAC3 inhibition. Mechanistically, GNAS KO-induced sensitization is independent of the canonical G-protein activities but unexpectedly mediated by viral mimicry-related interferon (IFN) responses, characterized by TBK1 and IRF3 activation, double-stranded RNA formation, and transposable element (TE) expression. GNAS KO additionally synergizes with HDAC3 inhibition to enhance CD8+ T cell-induced cytotoxicity. Moreover, we observe in human lymphoma patients that low GNAS expression is associated with high baseline TE expression and upregulated IFN signaling and shares common disrupted biological activities with GNAS KO in histone modification, mRNA processing, and transcriptional regulation. Collectively, our findings establish an unprecedented link between HDAC3 inhibition and viral mimicry in lymphoma. We suggest low GNAS expression as a potential biomarker that reflects viral mimicry priming for enhanced response to HDAC3 inhibition in the clinical treatment of lymphoma, especially the CREBBP wild-type cases.
引用
- He MY, Tong KI, Liu T, et al. GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma. Leukemia. 2024. PMID: 39117798. doi:10.1038/s41375-024-02325-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。